1. National Institute for Health and Care Excellence. Filgotinib for treating moderate to severe rheumatoid arthritis. Technology appraisal guidance [TA676]. London: NICE; 24 Feb 2021. https://www.nice.org.uk/guidance/ta676. Accessed 10 Jun 2021
2. Gilead. A randomized, double-blind, placebo- and active-controlled, multicenter, phase 3 study to assess the efficacy and safety of filgotinib administered for 52 weeks in combination with methotrexate to subjects with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate (FINCH 1) clinical study report. Gilead; 2020
3. Combe B, Kivitz A, Tanaka Y, Van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848–58.
4. Gilead. Randomized, double-blind, placebo-controlled, multicenter, phase 3 study to assess the efficacy and safety of filgotinib administered for 24 weeks in combination with conventional synthetic disease-modifying anti-rheumatic drug(s) (csDMARDs) to subjects with moderately to severely active rheumatoid arthritis who have an inadequate response to biologic DMARD(s) Treatment (FINCH 2). Clinical study report. Gilead; 2020
5. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–25.